Rilotumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Rilotumumab
Accession Number
DB11972
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • AMG 102
Categories
UNII
51WEW898IJ
CAS number
872514-65-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Rilotumumab.
AbituzumabThe risk or severity of adverse effects can be increased when Rilotumumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Rilotumumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rilotumumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Rilotumumab.
AducanumabThe risk or severity of adverse effects can be increased when Rilotumumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rilotumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Rilotumumab.
AmatuximabThe risk or severity of adverse effects can be increased when Rilotumumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911263
Wikipedia
Rilotumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentPart 1- Advanced Solid Tumors / Part 2- Advanced or Metastatic Gastric Cancer / Part 2- Advanced or Metastatic GEJ1
1, 2CompletedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Malignancies / Mestastatic Prostate Cancer / Prostate Cancer1
1, 2CompletedTreatmentColorectal Cancers / Gastrointestinal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Rectal Carcinoma1
1, 2CompletedTreatmentEsophageal Cancers / Esophagogastric Junction Adenocarcinoma / Malignant Neoplasm of Stomach1
1, 2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Tumors, Solid1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentMalignant Neoplasm of Esophagus / Malignant Neoplasm of Stomach1
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliosarcoma1
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2WithdrawnTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2, 3Active Not RecruitingTreatmentMET Positive / Recurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
3TerminatedTreatmentMalignant Neoplasm of Stomach2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:07 / Updated on June 04, 2019 07:29